1.Application of eye ward class in young doctors' comprehensive ability training
Yanling WANG ; Lihua LUO ; Tetsuya NISHIMURA
Chinese Journal of Medical Education Research 2012;11(2):220-222
To develop the basic skills of young ophthalmic doctors,The following means can be used:the fundus examination training,doctor-patient communication ability training,teaching ward round,ward small lectures,giving patients lectures,encouraging young doctors to participate in scientific research conference and providing convenient learning places etc.for them to actively implementing knowledge and promote their ability.Ward as the earliest classroom for ophthalmic young doctor has its unique advantages,which is advantageous to the quick and good growth of young ophthalmologists.
2.Mirtazapine provided remarkable relief for refractory nausea and vomiting by sunitinib and oxycodone in a patient with renal cancer
Hiroaki Shibahara ; Yumiko Tokura ; Tetsuya Isero ; Toshiki Etani ; Yousuke Ikegami ; Hiroyuki Kamiya ; Yoshihiro Hashimoto ; Yutaka Iwase ; Natsuko Uematsu ; Eri Imai ; Daisaku Nishimura
Palliative Care Research 2012;7(1):514-517
Introduction: Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) and the previous reports show that may reduce nausea by inhibition of the serotonin 5-HT3receptor. Case report: A 38-year-old woman with advanced renal cancer with distant metastases was administered by sunitinib and oxycodone. Refractory nausea and vomiting developed during the course and mirtazapine at a daily dose of 1.875 mg was begun. The patient's nausea improved during the next day, and furthermore, by increasing the daily dose to 3.75 mg, vomiting was also improved on the third day. The therapy could be continued without withdrawal of sunitinib and oxycodone due to digestive symptoms. Although somnolence might be induced at a daily dose of 15 mg, the present low-dose mirtazapine could improve digestive symptoms without somnolence. Conclusion: We conclude that low-dose mirtazapine is one effective option for refractory nausea and vomiting during administration of sunitinib and oxycodone.